Please disable your Ad Blocker to better interact with this website.

Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.
News

Informant Told Congress Russians Paid Big Money To Influence Clinton Over Uranium One Deal

Will this presidential election be the most important in American history?

The Clinton Foundation is in the news again regarding the Uranium One Deal.

Douglas Campbell, an FBI informant, gave details to Congress about an effort by the Russian government to influence then-Secretary of State Hillary Clinton by having a public relations firm provide free services to the Clinton Global Initiative.

According to news reports, Campell said the Russians had public relations firm APCO Worldwide use part of its $3 million lobbying funds for in-kind work for the president’s non-profit.

The goal of the effort was to make a positive impact on former President Bill Clinton so Hillary Clinton would give approval to the purchase of Canadian-based Uranium One by a Russian nuclear company.

Fox News reports:

In the statement, obtained by Fox News, Campbell said Russian executives told him that Moscow was hiring APCO Worldwide in an effort to influence the Obama administration and Hillary Clinton.

Campbell said Russian nuclear officials “told me at various times that they expected APCO to apply a portion of the $3 million annual lobbying fee it was receiving from the Russians to provide in-kind support for the Clinton’s Global Initiative.”

In 2010, the U.S. gave the green light allowing Uranium One to be purchased by Rosatom – a nuclear energy company owned by the Russian government.

Despite finding and reporting criminal behavior by Russians in the U.S. surrounding their nuclear energy interests which Campbell gave to the FBI, the Obama administration allowed the sale of Uranium One.

The Hill reports:

Campbell, whose work as an informant was first disclosed in a series of stories published last fall by The Hill, helped the FBI gather evidence as early as 2009 that the Russian nuclear industry was engaged in a kickback, bribery and racketeering scheme on U.S. soil. The criminal scheme, among other things, compromised the U.S. trucking firm that had the sensitive job of transporting uranium around America, Campbell testified.

APCO denied the charges made by Campbell and Democrats are attacking his credibility.

The purchase of Uranium One gave the Russians control of about 20 percent of the uranium in the U.S.

The Department of Justice is investigating the possibility the Clinton Foundation was engaged in a pay to play scheme.

Tom Borelli

Dr. Tom Borelli is a Newsmax TV contributor and radio commentator addressing political issues from a conservative grassroots perspective. As a columnist, he has written for The Washington Times and authored articles for Newsmax Magazine, Newsmax Insider and previously was a co-host with his wife Deneen Borelli on the SiriusXM Patriot channel. Dr. Borelli appeared on numerous television programs, including the highly ranked Fox News Channel’s “The O’Reilly Factor,” “Hannity,” “The Kelly File," and "America’s News Headquarters." He has also appeared on Fox Business Network’s “Making Money with Charles Payne” and “After the Bell” as well as TheBlaze TV’s "The Glenn Beck Program" and "Dana!" Prior to working for public policy organizations, Dr. Borelli was a managing partner with the investment advisory firm of Action Fund Management, LLC and a portfolio manager for the Free Enterprise Action Fund (FEAF) where he used shareholder activism to challenge corporations that sought to profit from the growth of government. During his 25 years with the Altria Group, Inc., he built a foundation in public policy and issues management, drawing from diverse experiences ranging from basic research to corporate affairs. Dr. Borelli served as science fellow for the U.S. House of Representatives' Committee on Science, Space, and Technology during the 100th Congress. Dr. Borelli has also published scientific papers on interferon and human leukemia.

Related Articles